# Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

> **NCT06843317** · PHASE1 · RECRUITING · sponsor: **Clover Biopharmaceuticals USA, LLC** · enrollment: 160 (estimated)

## Conditions studied

- RSV Infection

## Interventions

- **BIOLOGICAL:** Candidate vaccine, SCB-1019T
- **BIOLOGICAL:** AREXVY
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT06843317
- **Lead sponsor:** Clover Biopharmaceuticals USA, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-21
- **Primary completion:** 2026-03-03
- **Final completion:** 2026-06-03
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06843317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06843317, "Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06843317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*